Amyloidosis is a group of conditions in which a protein folds the wrong way and builds up as deposits, called amyloid, in the body’s organs. Over time, those deposits can make organs such as the heart, kidneys, nerves, and digestive tract work less well. It is not one disease but several, with different causes, symptoms, and treatments, which is why identifying the exact type matters so much.
If you or someone you love has just heard this word, it may feel like a lot to take in. We’ll go through the main types, the key symptoms to watch for, how doctors diagnose it, and how treatment has changed in recent years.
How Does Amyloidosis Happen?
Your body makes thousands of proteins, and each one has to fold into a particular shape to do its job. In amyloidosis, a protein misfolds, forming tiny fibers that stick together and settle in tissues.
Systemic amyloidosis is the misfolding of a person’s own proteins, forming abnormal fibrils that deposit in organs and cause progressive dysfunction.
Doctors name each type of amyloidosis after the protein involved. The “A” stands for amyloidosis, and the letters after it name the protein.
The three most discussed types are:
- AL amyloidosis: the protein comes from abnormal plasma cells (a kind of immune cell) in the bone marrow.
- ATTR amyloidosis: the protein is transthyretin, which can misfold due to aging (wild-type) or a genetic mutation (hereditary).
- AA amyloidosis: the protein is serum amyloid A, which rises during long-term inflammation.
Other, rarer forms exist. A specialist can tell you whether one of them applies to your situation.
The Main Types of Amyloidosis
AL Amyloidosis
AL stands for “light chain.” A 2024 overview in Frontiers in Hematology describes AL amyloidosis as a plasma cell disease, meaning the amyloid is derived from fragments of antibodies (light chains) produced by a group of abnormal plasma cells. AL is the most common type of systemic amyloidosis.
AL amyloidosis most often shows up first in the kidneys or the heart. The Frontiers authors note that the most frequent presentations are proteinuria (with or without kidney failure) or heart failure.
Because it involves abnormal plasma cells, AL amyloidosis is usually treated by blood specialists (hematologists) along with organ specialists.
ATTR Amyloidosis
ATTR amyloidosis involves the protein transthyretin. A 2025 review in the Journal of Clinical Medicine describes two forms:
- Wild-type ATTR (ATTRwt): linked with aging. It mainly affects men over 70, with more than 90% of cases in men, and it usually shows up as a heart condition.
- Hereditary ATTR (ATTRv): caused by a variant in the TTR gene and passed down in families. More than 130 variants are known, and they can cause mostly heart symptoms, mostly nerve symptoms, or both.
A 2024 mini-review in Frontiers in Cardiovascular Medicine adds that wild-type ATTR has been found in about 13% of people with a type of heart failure called heart failure with preserved ejection fraction. The authors say it may be underestimated in women.
AA Amyloidosis
AA amyloidosis is sometimes called “secondary” amyloidosis because it happens as a complication of another, long-lasting inflammatory condition. A 2022 review in Kidney Medicine lists causes such as inflammatory arthritis, periodic fever syndromes, and chronic infections. In the kidneys, it can lead to protein in the urine and reduced kidney function.
AA amyloidosis has been declining, reflecting better control of underlying inflammatory conditions. If you live with an inflammatory condition, that is encouraging news: staying connected to your care and keeping inflammation under control is the main way to address this complication.
Why the Type Matters
The three types above are treated in completely different ways. AL amyloidosis is treated by targeting the abnormal plasma cells. ATTR is treated with medicines that stabilize or lower transthyretin levels. AA is treated by controlling the underlying inflammation.
A treatment that works well for one type may not help another, which is why doctors put so much effort into identifying the exact protein before treating.
What Are the Symptoms of Amyloidosis?
Symptoms depend on which organs are affected, and they usually develop slowly. Early symptoms may be nonspecific. These include leg swelling and breathlessness, which often delay diagnosis. Organs commonly affected include the heart, kidneys, liver, nerves, soft tissues, and the digestive tract.
Possible Signs by Area
Heart
- Shortness of breath, especially with activity
- Swelling in the legs or ankles
- Fatigue
- Irregular heartbeat
Kidneys
- Foamy urine, which can reflect protein leaking into the urine
- Swelling, particularly in the legs
Nerves
- Numbness, tingling, or burning in the hands or feet
- Dizziness or light-headedness on standing (postural hypotension)
- Digestive changes such as diarrhea or constipation
Other
- An enlarged tongue (macroglossia) or a tendency to bruise or bleed easily
- Carpal tunnel syndrome in both hands, spinal stenosis, or a ruptured biceps tendon
Keeping Perspective
Almost every symptom on this list has far more common explanations, such as aging, a busy schedule, a pinched nerve, or ordinary heart and kidney issues.
Doctors tend to consider amyloidosis when several clues appear together, or when something doesn’t fit the usual pattern. One symptom on its own is rarely a reason to think of it.
How Is Amyloidosis Diagnosed?
Diagnosing amyloidosis usually takes more than one step, and it is normal for the process to feel slow.
Step One: Finding the Amyloid
Diagnosis relies on showing amyloid in tissue, usually with a special stain called Congo red, or on imaging with high specificity. The Frontiers in Hematology overview calls Congo red staining the gold standard.
A tissue sample (biopsy) has the highest chance of finding amyloid but carries some bleeding risk in certain organs. An abdominal fat aspirate, a less invasive option, is lower risk but is much less sensitive for ATTR.
Imaging can help too. Cardiac MRI and a bone scan with bone-seeking tracers are highly specific for cardiac involvement, and the bone scan is diagnostic of ATTR when no abnormal monoclonal protein is present in the blood or urine.
Step Two: Identifying the Type
Identifying the exact protein is essential. The Frontiers authors explain that typing, using immunohistochemistry or mass spectrometry, distinguishes AL from ATTR.
Another method is laser microdissection with mass spectrometry, although cost and complexity can limit access in smaller hospitals. If your care is at a smaller center, it is reasonable to ask whether a referral to a specialist amyloidosis center would be helpful.
Blood and urine tests that detect abnormal light chains also help distinguish AL from other types, and genetic testing is used when a hereditary form is suspected.
The 2025 ATTR review calls genetic testing mandatory once ATTR cardiomyopathy is confirmed, and recommends genetic counseling for relatives of people with hereditary disease.
Step Three: Staging
In AL amyloidosis, doctors also stage the disease before treatment, using blood markers such as NT-proBNP, troponin, and light chains. Staging helps estimate how the disease may behave and guides treatment decisions.
A Note on Gene Variants
Finding a gene variant is not the same as having the disease. A 2023 study in the Journal of the American Heart Association of the V122I variant in 278 Black participants aged 60 and older with heart failure found that 6.5% were carriers, and only 39% of carriers had ATTR cardiomyopathy.
The authors concluded that “genotype alone is insufficient for diagnosis.” The study was an interim report, but its message is: carrying a variant does not mean you will definitely develop amyloidosis.
How Is Amyloidosis Treated?
Treatment depends on the type, which organs are affected, and your overall health. This is an overview, not personal medical advice, and what’s available varies by country.
Supportive Care for Every Type
Supportive care, such as managing fluid balance and coordinating a team of specialists, is critical for all types. Supportive care aims to protect the organs and keep you comfortable, and it matters alongside any disease-specific treatment.
Treating AL Amyloidosis
Treatment for AL targets the abnormal plasma cells that make the light chains. In the 2021 ANDROMEDA trial, published in the New England Journal of Medicine, 388 people with newly diagnosed AL amyloidosis received a standard three-drug combination (bortezomib, cyclophosphamide, and dexamethasone) either with or without a medicine called daratumumab.
- A complete response in the blood-cell disease occurred in 53.3% of those who also received daratumumab, compared with 18.1% of those who did not.
- At six months, heart responses were 41.5% versus 22.2%, and kidney responses were 53.0% versus 23.9%.
- Survival without worsening of major organs or disease progression favored the daratumumab group.
- Common serious side effects included low white-cell counts, pneumonia, heart failure, and diarrhea. Deaths were similar between groups (27 and 29), mostly from amyloid-related heart disease.
The median follow-up was 11.4 months, so longer-term results matter too. The 2024 Frontiers overview adds that for younger, fit patients, a stem cell transplant after daratumumab-based treatment is considered a cornerstone of therapy, and that newer therapies borrowed from myeloma treatment are being studied.
Treating ATTR Amyloidosis
ATTR treatments fall into two main groups, as summarized in the 2025 review:
- TTR stabilizers, such as tafamidis and acoramidis, which help keep the protein from coming apart. In the ATTRibute-CM trial of acoramidis, published in 2024, hospitalizations for cardiovascular reasons were lower than with placebo (26.7% versus 42.6%), and the combined outcome favored acoramidis (win ratio 1.8).
- Gene silencers, such as vutrisiran and eplontersen, which lower how much transthyretin the body makes. In the HELIOS-B trial of 655 people with ATTR cardiomyopathy, the combined outcome of death and recurrent cardiovascular events occurred in 163 people on vutrisiran versus 202 on placebo.
Because the 2025 review stresses that treatment works best before the disease is advanced, it can help to raise questions early. It is not a cause for guilt if a diagnosis came late. Delay is very common because the symptoms are so easily mistaken for other things.
Treating AA Amyloidosis
Treatment centers on controlling the underlying inflammatory condition, which helps stabilize kidney function, reduce protein in the urine, and slow progression toward kidney failure. Tocilizumab, a medicine that blocks interleukin-6, was used in published biopsy-proven cases, including a person with long-standing rheumatoid arthritis who responded well.
Treatments Still Being Studied
Medicines aimed directly at clearing amyloid deposits from tissues remain largely investigational, and some have failed in trials. The 2025 ATTR review also describes experimental gene-editing and antibody approaches in earlier-stage trials. New options are being tested, but they are not yet standard care.
What Is the Outlook?
The outlook depends heavily on the type of amyloidosis, how early it is found, and which organs are affected. In AL amyloidosis, cardiac involvement is the main determinant of survival, and deeper responses to treatment in both the blood-cell disease and the organs are linked to better outcomes. Organ damage remains the main limit on life expectancy in both AL and ATTR.
It’s natural to want a single number, but study results describe groups, not individuals, and treatment has been changing quickly. Your own care team can talk through what the picture looks like for you, at whatever pace feels right.
Living With Amyloidosis
Whether the diagnosis is new or you’ve lived with it for a while, a few things can make daily life more manageable.
- Build a care team you trust. Because amyloidosis can involve multiple organs, a multidisciplinary team is essential. A specialist amyloidosis center can help coordinate this.
- Bring someone to appointments. A second person can help by listening and taking notes.
- Ask for plain-language explanations. You’re allowed to say, “Can you explain that another way?”
- Pace yourself. Fatigue and breathlessness are real. Resting is part of managing the condition, not giving up.
- Ask about practical help. Social workers and patient organizations can sometimes assist with costs, transportation, and paperwork.
- Look after your mind. A diagnosis like this can bring worry, grief, or low mood, and counseling or peer support are legitimate parts of care.
If You’re a Family Member
If a relative has hereditary ATTR, you may feel a pull to find out your own status, or a strong wish not to. Both feelings are valid. Genetic counseling may provide you with information and the space to decide at your own pace.
If You’ve Been Dismissed Before
Many people spend a long time being told their symptoms are “just aging,” “just stress,” or “just your heart.” The research says delays are common and that wild-type ATTR may be underrecognized in women. You are allowed to ask, “Could we look for a less common cause?” and to ask for a referral if your questions aren’t being answered.
Questions to Bring to Your Care Team
- Which type of amyloidosis do I have, and how was it confirmed?
- Which organs are affected, and how will we monitor them?
- What treatment options fit my situation, and what are the possible side effects?
- Is there a specialist amyloidosis center I can be referred to?
- Should my relatives be offered genetic counseling?
- Which symptoms should make me call sooner than my next appointment?
When to Seek Medical Care
Please contact a healthcare provider if you notice:
- Persistent numbness, tingling, or burning in your hands or feet
- Swelling in your legs along with new shortness of breath
- Foamy urine together with swelling
- Fainting or repeated dizziness when you stand
- Several of the clues above together, or a family history of amyloidosis
Seek emergency care right away for chest pain, severe trouble breathing, fainting, or signs of a stroke.
For Anyone Feeling Anxious About This
If you’ve been reading about amyloidosis and your mind is racing, you’re not overreacting by wanting answers. Here are some things to hold onto:
- Most of the symptoms described here have everyday explanations. Swelling, fatigue, tingling, and carpal tunnel syndrome are very common, and having one of them is not a sign that you have amyloidosis.
- Diagnosis is careful for good reason. The step-by-step process is built to confirm the exact type, so treatment can be matched to it.
- A gene variant is not a sentence. In the V122I study, most carriers did not have ATTR cardiomyopathy.
- Treatment has expanded. There are now approved options for several types, and newer ones are under study.
- You are not on your own. Specialist centers, genetic counselors, and patient communities exist for exactly this.
- Worry can be treated too. If anxious thoughts are taking over, talking to a therapist or your doctor is a strong, practical step.
Take it one step at a time. Reading about a condition is not the same as having it.
Frequently Asked Questions
What is amyloidosis in simple terms?
Amyloidosis is a group of conditions in which a misfolded protein builds up as deposits, called amyloid, in organs such as the heart, kidneys, and nerves. There are several types, named after the protein involved, and each is treated differently.
What are the main types of amyloidosis?
The three most discussed types are AL amyloidosis, which arises from abnormal plasma cells; ATTR amyloidosis, which involves the protein transthyretin and can be wild-type or hereditary; and AA amyloidosis, which results from long-lasting inflammation. Rarer forms also exist.
Is amyloidosis cancer?
Amyloidosis is a protein-buildup condition. AL amyloidosis comes from abnormal plasma cells, so it is usually treated by blood specialists, and newer treatments have been adapted from myeloma care. ATTR and AA amyloidosis involve different proteins and are treated differently.
Is amyloidosis hereditary?
Only some forms are. Hereditary ATTR is caused by a variant in the TTR gene and is passed down in families. AL, AA, and wild-type ATTR are not inherited in this way. Having a variant does not guarantee that you will develop the disease.
How is amyloidosis diagnosed?
Doctors usually confirm amyloid in tissue with Congo red staining, sometimes through a biopsy or, in the heart, with imaging such as a bone scan or cardiac MRI. They then identify the exact protein, often with mass spectrometry, and order blood, urine, and genetic tests as needed.
Can amyloidosis be treated?
Yes. Treatment depends on the type. AL amyloidosis is treated by targeting abnormal plasma cells; ATTR by medicines that stabilize or lower transthyretin; and AA by controlling the underlying inflammation. Supportive care helps manage symptoms across all types.
Does swelling or tingling mean I have amyloidosis?
Probably not. Swelling, tingling, fatigue, and carpal tunnel syndrome are very common and have many causes. Amyloidosis is usually considered only when several clues occur together or when a doctor sees a pattern that does not fit the usual explanations.